Pharmacokinetic Modeling of Neutralizing ADA Effects in Translational Development

Anti-drug antibodies (ADAs), especially those with neutralizing potential, can significantly affect pharmacokinetics (PK) and complicate translational predictions. Understanding and accounting for neutralizing ADA early in drug development is critical for generating reliable PK models and accurate dose projections across species.

Join Certara’s expert-led session where we’ll explore how neutralizing ADAs impact PK, why these effects are often not translatable between species, and the risks of ignoring ADA in your nonclinical data package. Through real-world case studies, we’ll demonstrate how structural and covariate models, built in Phoenix® NLME can be used to support interspecies scaling and human dose prediction when neutralizing ADA is present or suspected.